Using blood markers to guide oxygen therapy after severe brain injury
Biomarkers in the Hyperbaric Oxygen in Brain Injury Treatment Trial
This project tests whether blood markers can help guide hyperbaric oxygen treatment for people with severe traumatic brain injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10697359 on NIH RePORTER |
What this research studies
If you or a loved one has a severe traumatic brain injury and is unresponsive, this work looks at whether specific blood proteins can show who is responding to hyperbaric oxygen therapy. Researchers will collect blood samples (including measures like GFAP, NfL, and hsCRP) and clinical data from critically ill patients in the ICU and compare marker changes over time with recovery. The team aims to use those markers to tailor treatment dosing and to pick patients most likely to benefit from the therapy. The work is done in hospital ICU settings where patients are intubated and sedated.
Who could benefit from this research
Good fit: Adults with severe traumatic brain injury (Glasgow Coma Scale below 8) who are intubated and receiving ICU care are the intended candidates for participation.
Not a fit: People with mild or moderate TBI, chronic brain injuries, or those not eligible for hyperbaric oxygen treatment are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this could help doctors personalize hyperbaric oxygen treatment and improve patient selection for trials, potentially improving recovery after severe TBI.
How similar studies have performed: Prior studies show GFAP and NfL can indicate brain injury and predict outcomes, but using these markers to guide hyperbaric oxygen therapy is a newer and not yet proven approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Korley, Frederick Kofi — University of Michigan at Ann Arbor
- Study coordinator: Korley, Frederick Kofi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.